Sugi Predict

Sugi Predict / Compounds / SCHEMBL7895006

SCHEMBL7895006

SCHEMBL7895006

CCCCCCCCCCCCN(CCCC)C(C)=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 3/20 0.52
▸ CA1 P00915 3/20 0.52
▸ CA9 Q16790 3/20 0.52
▸ CA2 P00918 1/20 0.50
▸ MMP1 P03956 1/20 0.48
▸ MMP2 P08253 1/20 0.48
▸ MMP3 P08254 1/20 0.48
▸ MMP8 P22894 1/20 0.48
▸ MGLL Q99685 1/20 0.45
▸ ZDHHC20 Q5W0Z9 2/20 0.44
▸ ZDHHC2 Q9UIJ5 1/20 0.44
▸ DNM1 Q05193 3/20 0.44
▸ CES2 O00748 3/20 0.42
▸ CES1 P23141 3/20 0.42
▸ ALDH1A1 P00352 2/20 0.41
▸ ALDH2 P05091 1/20 0.41
▸ PPARG P37231 3/20 0.41
▸ PPARD Q03181 3/20 0.41
▸ PPARA Q07869 3/20 0.41
▸ TSHR P16473 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19574077 1.00 CA12 (0.52) CA12CA1CA9CA2MMP1
SCHEMBL6940598 0.98 CA12 (0.52) CA12CA1CA9CA2MMP1
SCHEMBL4139404 0.98 CA12 (0.52) CA12CA1CA9CA2MMP1
SCHEMBL4149053 0.98 CA12 (0.52) CA12CA1CA9CA2MMP1
SCHEMBL2482724 0.98 CA12 (0.52) CA12CA1CA9CA2MMP1
SCHEMBL4163491 0.98 CA12 (0.52) CA12CA1CA9CA2MMP1
SCHEMBL4155109 0.98 CA12 (0.52) CA12CA1CA9CA2MMP1
SCHEMBL11343070 0.98 CA12 (0.52) CA12CA1CA9CA2MMP1
SCHEMBL8431297 0.98 CA12 (0.52) CA12CA1CA9CA2MMP1
SCHEMBL1742678 0.98 CA12 (0.52) CA12CA1CA9CA2MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2916820-A1 DELIVERY OF BIOLOGICALLY-ACTIVE AGENTS USING VOLATILE, HYDROPHOBIC SOLVENTS Rochal Industries, LLC (US) 2015-09-16 — — EP claimed
US-8852648-B2 Delivery of biologically-active agents using volatile, hydrophobic solvents ROCHAL INDUSTRIES, LLP (US) 2014-10-07 — — US claimed
WO-2014074289-A1 DELIVERY OF BIOLOGICALLY-ACTIVE AGENTS USING VOLATILE, HYDROPHOBIC SOLVENTS ROCHAL INDUSTRIES, LLP (US) 2014-05-15 — — WO claimed
US-20140127320-A1 DELIVERY OF BIOLOGICALLY-ACTIVE AGENTS USING VOLATILE, HYDROPHOBIC SOLVENTS ROCHAL INDUSTRIES, LLP (US) 2014-05-08 — — US claimed
EP-0268220-B1 PENETRATION ENHANCERS FOR TRANSDERMAL DELIVERY OF SYSTEMIC AGENTS WHITBY RESEARCH, Inc. (US) 1992-05-20 — — EP claimed
US-4808414-A DRUG DELIVERY BY SKIN ABSORPTION NELSON RESEARCH & DEVELOPMENT CO. (US) 1989-02-28 — — US claimed
EP-0268220-A2 Penetration enhancers for transdermal delivery of systemic agents WHITBY RESEARCH, Inc. (US) 1988-05-25 — — EP claimed
US-20260027089-A1 MrgprX2 Antagonists for the Treatment of Inflammatory Disorders DERMIRA INC (US) 2026-01-29 — — US disclosed
US-12502380-B2 MrgprX2 antagonists for the treatment of inflammatory disorders DERMIRA, INC. (US) 2025-12-23 — — US disclosed
US-20250057816-A1 MrgprX2 Antagonists for the Treatment of Inflammatory Disorders DERMIRA, INC. 2025-02-20 — — US disclosed
US-20230390265-A1 IRAK4 Inhibitors and Topical Uses Thereof DERMIRA, INC. 2023-12-07 — — US disclosed
US-20230321124-A1 ROR gamma t Inhibitors and Topical Uses Thereof DERMIRA, INC. 2023-10-12 — — US disclosed
EP-2916820-B1 DELIVERY OF BIOLOGICALLY-ACTIVE AGENTS USING VOLATILE, HYDROPHOBIC SOLVENTS ROCHAL TECH LLC (US) 2023-10-11 — — EP disclosed
EP-0329669-A1 COMPOSITIONS COMPRISING N,N-DIALKYLALKANAMIDES AND THEIR USES Whitby Research Incorporated (US) 1989-08-30 — — EP disclosed
US-4808414-A DRUG DELIVERY BY SKIN ABSORPTION NELSON RESEARCH & DEVELOPMENT CO. (US) 1989-02-28 — — US disclosed
EP-0268220-A2 Penetration enhancers for transdermal delivery of systemic agents WHITBY RESEARCH, Inc. (US) 1988-05-25 — — EP disclosed
WO-1988002216-A1 COMPOSITIONS COMPRISING N,N-DIALKYLALKANAMIDES AND THEIR USES NELSON RESEARCH AND DEVELOPMENT COMPANY (US) 1988-04-07 — — WO disclosed
US-4716060-A ACYCLIC OR HETEROCYCLIC TERTIARY AMIDE RAJADHYAKSHA VITHAL J (US) 1987-12-29 — — US disclosed
US-4716060-A ACYCLIC OR HETEROCYCLIC TERTIARY AMIDE RAJADHYAKSHA VITHAL J (US) 1987-12-29 — — US disclosed
US-4519950-A Acetal group-containing non-ionic surfactants BASF WYANDOTTE CORPORATION (US) 1985-05-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260027089-A1 MrgprX2 Antagonists for the Treatment of Inflammatory Disorders MRGPRX2, MRGPRX1, MRGPRX4 CA12 3822/4885CA1 4428/4885CA9 3169/4885
US-12502380-B2 MrgprX2 antagonists for the treatment of inflammatory disorders MRGPRX2, MRGPRX1, MRGPRX4 CA12 3951/4885CA1 4780/4885CA9 3267/4885
US-20230321124-A1 ROR gamma t Inhibitors and Topical Uses Thereof RORC, RORB, RORA CA12 1576/4885CA1 2036/4885CA9 1769/4885
US-20250057816-A1 MrgprX2 Antagonists for the Treatment of Inflammatory Disorders MRGPRX2, MRGPRX1, MRGPRX4 CA12 3951/4885CA1 4780/4885CA9 3267/4885
US-20230390265-A1 IRAK4 Inhibitors and Topical Uses Thereof IRAK4, IRAK2, IRAK3 CA12 4608/4885CA1 4881/4885CA9 4681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.